MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89

Overview

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions

  • Diabetic Nephropathy
  • Ventricular Dysfunction
  • Hypertension
  • Marfan Syndrome
  • Ischemic Stroke

FDA Approved Products

Losartan Potassium
Manufacturer:Quality Care Products, LLC
Route:ORAL
Strength:50 mg in 1 1
Approved: 2019/06/28
NDC:55700-769
losartan potassium and hydrochlorothiazide
Manufacturer:Unichem Pharmaceuticals (USA), Inc.
Route:ORAL
Strength:50 mg in 1 1
Approved: 2023/04/05
NDC:29300-190
losartan potassium and hydrochlorothiazide
Manufacturer:Unichem Pharmaceuticals (USA), Inc.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/04/05
NDC:29300-191
Losartan Potassium and Hydrochlorothiazide
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2024/02/13
NDC:70518-0786
losartan potassium and hydrochlorothiazide
Manufacturer:Unichem Pharmaceuticals (USA), Inc.
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/04/05
NDC:29300-192

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath